![Sharon Hanegraaf](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sharon Hanegraaf is Vice President-Regulatory Affairs at Argenica Therapeutics Ltd. since 2025.
Formerly, Ms. Hanegraaf was Vice President-Drug Development & Strategy at Kinoxis Therapeutics Pty Ltd.
| Sociétés | Poste | Début |
|---|---|---|
| ARGENICA THERAPEUTICS LIMITED | Corporate Officer/Principal | 11/08/2025 |
| Sociétés | Poste | Fin |
|---|---|---|
Kinoxis Therapeutics Pty Ltd.
 Kinoxis Therapeutics Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in conducting biotechnology research | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 2 |
|---|---|
Kinoxis Therapeutics Pty Ltd.
Kinoxis Therapeutics Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in conducting biotechnology research | Commercial Services |
Argenica Therapeutics Ltd.
 Argenica Therapeutics Ltd. BiotechnologyHealth Technology Develops novel neuro protective therapeutics to reduce brain damage | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
